Skip to main content
NCBI home page
British Heart Journal logoLink to British Heart Journal
. 1993 Mar;69(3):215–222. doi: 10.1136/hrt.69.3.215

Early treatment with captopril after acute myocardial infarction.

S G Ray 1, M Pye 1, K G Oldroyd 1, J Christie 1, D T Connelly 1, D B Northridge 1, I Ford 1, J J Morton 1, H J Dargie 1, S M Cobbe 1
PMCID: PMC1024983  PMID: 8461219

Abstract

OBJECTIVES--To determine the effects of early treatment with captopril on haemodynamic function, neuroendocrine biochemistry, left ventricular structure, clinical outcome, and exercise capacity over one year from acute myocardial infarction. DESIGN--Randomised, double blind, placebo controlled comparison of captopril and placebo. SETTING--Coronary care units and cardiology departments of two university teaching hospitals in Glasgow. PATIENTS--99 haemodynamically stable patients with acute myocardial infarction, selected on clinical grounds as being at risk of late ventricular dilatation. INTERVENTION--Captopril or identical placebo started between six and 24 hours after start of symptoms and continued for 12 months. Target maintenance dose was 25 mg three times a day. MAIN OUTCOME MEASURES--(a) Acute haemodynamic effects of treatment; (b) neuroendocrine biochemistry from admission to two months; and (c) change in echocardiographic measures of left ventricular size, clinical outcome, and exercise capacity after 12 months of treatment with a separate analysis of the effects of one month of treatment withdrawal on left ventricular volumes. RESULTS--Captopril caused acute reductions in mean (SEM) pulmonary artery pressure (2.48 (0.69) mm Hg) and systemic vascular resistance (260 (103)) dyn.s.cm-5). Over the first 10 hours captopril reduced mean arterial pressure by 12.1 (2.4) mm Hg compared with 3.8 (1.9) mm Hg in the placebo group. No patient had to be withdrawn from the captopril group because of hypotension. From day 1 onwards systolic and diastolic arterial pressures in the captopril treated group were slightly but not significantly lower than on placebo. There was no difference in the incidence of ventricular or supraventricular arrhythmia with treatment. Captopril prevented the day 3 peak in angiotensin II that occurred in the placebo group (peak concentration (interquartile range): 10.1 (4.8-19.4) pg/ml v 16.8 (4.3-46.3) pg/ml)) but had no effect on atrial natriuretic factor, arginine vasopressin, or catecholamines. Plasma atrial natriuretic factor remained above normal in both groups at two months after infarction. After one year left ventricular volume indices had increased less on captopril than on placebo: left ventricular end systolic volume index 5.4 ml/m2 v 14.7 ml/m2 (95% confidence interval (95% CI) of difference -14.6 to -3.9; p = 0.0011); left ventricular end diastolic volume index 8.4 ml/m2 v 19.0 ml/m2 (95% CI of difference, -17.0 to -4.2; p = 0.0016). Withdrawal of captopril for one month did not affect ventricular volumes. There was no difference in exercise capacity. CONCLUSIONS--Captopril started between six and 24 hours after acute myocardial infarction is not associated with significant hypotension. It suppresses activation of the renin angiotensin system but has no effect on plasma concentrations of other neurohormones. Atrial natriuretic factor remains raised at two months after myocardial infarction. Captopril significantly decreases left ventricular dilatation. This effect is not lost after one month of treatment withdrawal and is thus due to an alteration of left ventricular structure and not to a short lived haemodynamic action of captopril. Long-term treatment with captopril does not result in improved aerobic exercise capacity after acute myocardial infarction.

Full text

PDF
215

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ball S. G., Tree M., Morton J. J., Inglis G. C., Fraser R. Circulating dopamine: its effect on the plasma concentrations of catecholamines, renin, angiotensin, aldosterone and vasopressin in the conscious dog. Clin Sci (Lond) 1981 Oct;61(4):417–422. doi: 10.1042/cs0610417. [DOI] [PubMed] [Google Scholar]
  2. Bland J. M., Altman D. G. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986 Feb 8;1(8476):307–310. [PubMed] [Google Scholar]
  3. Bonaduce D., Petretta M., Villari B., Breglio R., Conforti G., Montemurro M. V., Lanzillo T., Morgano G. Effects of late administration of tissue-type plasminogen activator on left ventricular remodeling and function after myocardial infarction. J Am Coll Cardiol. 1990 Dec;16(7):1561–1568. doi: 10.1016/0735-1097(90)90301-5. [DOI] [PubMed] [Google Scholar]
  4. Cleland J., Semple P., Hodsman P., Ball S., Ford I., Dargie H. Angiotensin II levels, hemodynamics, and sympathoadrenal function after low-dose captopril in heart failure. Am J Med. 1984 Nov;77(5):880–886. doi: 10.1016/0002-9343(84)90530-8. [DOI] [PubMed] [Google Scholar]
  5. De Mey J. G., Defreyn G., Lenaers A., Calderon P., Roba J. Arterial reactivity, blood pressure, and plasma levels of atrial natriuretic peptides in normotensive and hypertensive rats: effects of acute and chronic administration of atriopeptin III. J Cardiovasc Pharmacol. 1987 May;9(5):525–535. doi: 10.1097/00005344-198705000-00004. [DOI] [PubMed] [Google Scholar]
  6. Eaton L. W., Weiss J. L., Bulkley B. H., Garrison J. B., Weisfeldt M. L. Regional cardiac dilatation after acute myocardial infarction: recognition by two-dimensional echocardiography. N Engl J Med. 1979 Jan 11;300(2):57–62. doi: 10.1056/NEJM197901113000202. [DOI] [PubMed] [Google Scholar]
  7. Fontana F., Bernardi P., Spagnolo N., Capelli M. Plasma atrial natriuretic factor in patients with acute myocardial infarction. Eur Heart J. 1990 Sep;11(9):779–787. doi: 10.1093/oxfordjournals.eurheartj.a059797. [DOI] [PubMed] [Google Scholar]
  8. Franciosa J. A. Exercise testing in chronic congestive heart failure. Am J Cardiol. 1984 May 15;53(10):1447–1450. doi: 10.1016/s0002-9149(84)91041-5. [DOI] [PubMed] [Google Scholar]
  9. Gadsbøll N., Høilund-Carlsen P. F., Badsberg J. H., Stage P., Marving J., Lønborg-Jensen H. Late ventricular dilatation in survivors of acute myocardial infarction. Am J Cardiol. 1989 Nov 1;64(16):961–966. doi: 10.1016/0002-9149(89)90790-x. [DOI] [PubMed] [Google Scholar]
  10. Gavras H., Kremer D., Brown J. J., Gray B., Lever A. F., MacAdam R. F., medina A., Morton J. J., Robertson J. I. Angiotensin- and norepinephrine-induced myocardial lesions: experimental and clinical studies in rabbits and man. Am Heart J. 1975 Mar;89(3):321–332. doi: 10.1016/0002-8703(75)90082-4. [DOI] [PubMed] [Google Scholar]
  11. Hochman J. S., Bulkley B. H. Expansion of acute myocardial infarction: an experimental study. Circulation. 1982 Jun;65(7):1446–1450. doi: 10.1161/01.cir.65.7.1446. [DOI] [PubMed] [Google Scholar]
  12. Hutchins G. M., Bulkley B. H. Infarct expansion versus extension: two different complications of acute myocardial infarction. Am J Cardiol. 1978 Jun;41(7):1127–1132. doi: 10.1016/0002-9149(78)90869-x. [DOI] [PubMed] [Google Scholar]
  13. Jeremy R. W., Allman K. C., Bautovitch G., Harris P. J. Patterns of left ventricular dilation during the six months after myocardial infarction. J Am Coll Cardiol. 1989 Feb;13(2):304–310. doi: 10.1016/0735-1097(89)90503-2. [DOI] [PubMed] [Google Scholar]
  14. Jeremy R. W., Hackworthy R. A., Bautovich G., Hutton B. F., Harris P. J. Infarct artery perfusion and changes in left ventricular volume in the month after acute myocardial infarction. J Am Coll Cardiol. 1987 May;9(5):989–995. doi: 10.1016/s0735-1097(87)80298-x. [DOI] [PubMed] [Google Scholar]
  15. Kannel W. B., Sorlie P., McNamara P. M. Prognosis after initial myocardial infarction: the Framingham study. Am J Cardiol. 1979 Jul;44(1):53–59. doi: 10.1016/0002-9149(79)90250-9. [DOI] [PubMed] [Google Scholar]
  16. Levine T. B., Olivari M. T., Garberg V., Sharkey S. W., Cohn J. N. Hemodynamic and clinical response to enalapril, a long-acting converting-enzyme inhibitor, in patients with congestive heart failure. Circulation. 1984 Mar;69(3):548–553. doi: 10.1161/01.cir.69.3.548. [DOI] [PubMed] [Google Scholar]
  17. Mann F. E., Lang R. E., Leidig M., Ritz E. Effect of angiotensin I converting enzyme inhibition on circulating atrial natriuretic peptide in humans. Klin Wochenschr. 1986;64 (Suppl 6):13–15. [PubMed] [Google Scholar]
  18. Mattioli G., Ricci S., Rigo R., Fusaro M. T., Cappello C. Effects of captopril in heart failure complicating acute myocardial infarction and persistence of acute haemodynamic effects in chronic heart failure after 3 years of treatment. Postgrad Med J. 1986;62 (Suppl 1):164–166. [PubMed] [Google Scholar]
  19. McAlpine H. M., Morton J. J., Leckie B., Rumley A., Gillen G., Dargie H. J. Neuroendocrine activation after acute myocardial infarction. Br Heart J. 1988 Aug;60(2):117–124. doi: 10.1136/hrt.60.2.117. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Millar J. A., Leckie B. J., Morton J. J., Jordan J., Tree M. A microassay for active and total renin concentration in human plasma based on antibody trapping. Clin Chim Acta. 1980 Feb 14;101(1):5–15. doi: 10.1016/0009-8981(80)90050-9. [DOI] [PubMed] [Google Scholar]
  21. Morton J. J., Connell J. M., Hughes M. J., Inglis G. C., Wallace E. C. The role of plasma osmolality, angiotensin II and dopamine in vasopressin release in man. Clin Endocrinol (Oxf) 1985 Aug;23(2):129–138. doi: 10.1111/j.1365-2265.1985.tb00207.x. [DOI] [PubMed] [Google Scholar]
  22. Morton J. J., Webb D. J. Measurement of plasma angiotensin II. Clin Sci (Lond) 1985 Apr;68(4):483–484. doi: 10.1042/cs0680483. [DOI] [PubMed] [Google Scholar]
  23. Nabel E. G., Topol E. J., Galeana A., Ellis S. G., Bates E. R., Werns S. W., Walton J. A., Muller D. W., Schwaiger M., Pitt B. A randomized placebo-controlled trial of combined early intravenous captopril and recombinant tissue-type plasminogen activator therapy in acute myocardial infarction. J Am Coll Cardiol. 1991 Feb;17(2):467–473. doi: 10.1016/s0735-1097(10)80117-2. [DOI] [PubMed] [Google Scholar]
  24. Ngo L., Vesely D. L., Bissett J. K., Murphy M. L., Dinh H., Seth R., Sallman A. L., Rico D. M., Winters C. J., Wyeth R. P. Acute and sustained release of atrial natriuretic factor with acute myocardial infarction. Am Heart J. 1989 Nov;118(5 Pt 1):893–900. doi: 10.1016/0002-8703(89)90220-2. [DOI] [PubMed] [Google Scholar]
  25. Pfeffer M. A., Braunwald E., Moyé L. A., Basta L., Brown E. J., Jr, Cuddy T. E., Davis B. R., Geltman E. M., Goldman S., Flaker G. C. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992 Sep 3;327(10):669–677. doi: 10.1056/NEJM199209033271001. [DOI] [PubMed] [Google Scholar]
  26. Pfeffer M. A., Lamas G. A., Vaughan D. E., Parisi A. F., Braunwald E. Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med. 1988 Jul 14;319(2):80–86. doi: 10.1056/NEJM198807143190204. [DOI] [PubMed] [Google Scholar]
  27. Picard M. H., Wilkins G. T., Ray P. A., Weyman A. E. Natural history of left ventricular size and function after acute myocardial infarction. Assessment and prediction by echocardiographic endocardial surface mapping. Circulation. 1990 Aug;82(2):484–494. doi: 10.1161/01.cir.82.2.484. [DOI] [PubMed] [Google Scholar]
  28. Pletka P., Kenyon J. R., Snell M., Cohen S. L., Owen K., Mowbray J. F., Hulme B., Thompson A. E., Porter K. A., Leigh D. A. Cadaveric renal transplantation. An analysis of 65 cases. Lancet. 1969 Jan 4;1(7584):1–6. doi: 10.1016/s0140-6736(69)90981-7. [DOI] [PubMed] [Google Scholar]
  29. Richards A. M., Rao G., Espiner E. A., Yandle T. Interaction of angiotensin converting enzyme inhibition and atrial natriuretic factor. Hypertension. 1989 Mar;13(3):193–199. doi: 10.1161/01.hyp.13.3.193. [DOI] [PubMed] [Google Scholar]
  30. Richards A. M., Tonolo G., McIntyre G. D., Leckie B. J., Robertson J. I. Radio-immunoassay for plasma alpha human atrial natriuretic peptide: a comparison of direct and pre-extracted methods. J Hypertens. 1987 Apr;5(2):227–236. doi: 10.1097/00004872-198704000-00015. [DOI] [PubMed] [Google Scholar]
  31. Riegger G. A., Kochsiek K. Vasopressin, renin and norepinephrine levels before and after captopril administration in patients with congestive heart failure due to idiopathic dilated cardiomyopathy. Am J Cardiol. 1986 Aug 1;58(3):300–303. doi: 10.1016/0002-9149(86)90066-4. [DOI] [PubMed] [Google Scholar]
  32. Rouleau J. L., Bichet D., Kortas C. Atrial natriuretic peptide in congestive heart failure: postural changes and reset with chronic captopril therapy. Am Heart J. 1988 May;115(5):1060–1067. doi: 10.1016/0002-8703(88)90077-4. [DOI] [PubMed] [Google Scholar]
  33. Sharpe N., Murphy J., Smith H., Hannan S. Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction. Lancet. 1988 Feb 6;1(8580):255–259. doi: 10.1016/s0140-6736(88)90347-9. [DOI] [PubMed] [Google Scholar]
  34. Sharpe N., Smith H., Murphy J., Greaves S., Hart H., Gamble G. Early prevention of left ventricular dysfunction after myocardial infarction with angiotensin-converting-enzyme inhibition. Lancet. 1991 Apr 13;337(8746):872–876. doi: 10.1016/0140-6736(91)90202-z. [DOI] [PubMed] [Google Scholar]
  35. Starling M. R., Crawford M. H., Sorensen S. G., Levi B., Richards K. L., O'Rourke R. A. Comparative accuracy of apical biplane cross-sectional echocardiography and gated equilibrium radionuclide angiography for estimating left ventricular size and performance. Circulation. 1981 May;63(5):1075–1084. doi: 10.1161/01.cir.63.5.1075. [DOI] [PubMed] [Google Scholar]
  36. Swedberg K., Eneroth P., Kjekshus J., Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation. 1990 Nov;82(5):1730–1736. doi: 10.1161/01.cir.82.5.1730. [DOI] [PubMed] [Google Scholar]
  37. Tortoledo F. A., Quinones M. A., Fernandez G. C., Waggoner A. D., Winters W. L., Jr Quantification of left ventricular volumes by two-dimensional echocardiography: a simplified and accurate approach. Circulation. 1983 Mar;67(3):579–584. doi: 10.1161/01.cir.67.3.579. [DOI] [PubMed] [Google Scholar]
  38. Warren S. E., Royal H. D., Markis J. E., Grossman W., McKay R. G. Time course of left ventricular dilation after myocardial infarction: influence of infarct-related artery and success of coronary thrombolysis. J Am Coll Cardiol. 1988 Jan;11(1):12–19. doi: 10.1016/0735-1097(88)90159-3. [DOI] [PubMed] [Google Scholar]
  39. Wenting G. J., Man in't veld A. J., Woittiez A. J., Boomsma F., Laird-Meeter K., Simoons M. L., Hugenholtz P. G., Schalekamp M. A. Effects of captopril in acute and chronic heart failure. Correlations with plasma levels of noradrenaline, renin, and aldosterone. Br Heart J. 1983 Jan;49(1):65–76. doi: 10.1136/hrt.49.1.65. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. White H. D., Norris R. M., Brown M. A., Brandt P. W., Whitlock R. M., Wild C. J. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation. 1987 Jul;76(1):44–51. doi: 10.1161/01.cir.76.1.44. [DOI] [PubMed] [Google Scholar]
  41. Wilkins M. R., Lewis H. M., West M. J., Kendall M. J., Lote C. J. Captopril reduces the renal response to intravenous atrial natriuretic peptide in normotensives. J Hum Hypertens. 1987 Jun;1(1):47–51. [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES